The safety and ablation efficacy of ultrasound-guided high-intensity focused ultrasound ablation for desmoid tumors

Zhang, Rong; Chen, Jin-Yun; Li, Kequan; Xiao, Zhibo; Mo, Shaojiang; Chen, Li; Chen, Wenzhi

doi:10.1080/02656736.2021.1894359

Cited by 22 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other local therapies like cryoablation (a clinical trial was published after our search), radiofrequency ablation, and high-frequency ultrasound techniques are potential alternatives with good local control outcomes and improved quality of life. [38][39][40] One of the main limitations of this review is the low quality of the included trials. Of the 14 studies, only one was considered as high quality, according to the CONSORT 2010 checklist.…”

Section: Discussionmentioning

confidence: 99%

“…Because of these potential negative long‐term side effects, radiotherapy is nowadays restricted to highly symptomatic patients for whom no other valuable alternative is available. Other local therapies like cryoablation (a clinical trial was published after our search), radiofrequency ablation, and high‐frequency ultrasound techniques are potential alternatives with good local control outcomes and improved quality of life 38–40 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical trials in desmoid‐type fibromatosis in children and adults: A systematic review

Maren

Noesel

Husson

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Desmoid-type fibromatosis (DTF) is a rare locally aggressive soft tissue neoplasm, which occurs in children and adults, with a peak incidence in young adults. For the majority of the patients, DTF is a chronic and symptomatic disease, which affects health-related quality of life. Systemic treatment regimens tend to differ for patients treated by pediatric oncologists compared to medical oncologists. This systematic review identified 14 clinical trials in children and adults with DTF. Tumor response and progression-free survival rates varied widely between studies and study populations.Treatment choices for patients with DTF are based on a paucity of (randomized) trials.Treatment principles of DTF are similar in pediatric and adult oncology, but the treatment itself is different. This seems mostly driven by a lack of tyrosine kinase inhibitor (TKI) accessibility in pediatric oncology. An insufficient number of studies examined patient-reported outcomes, which are extremely important for patients with a chronic disease like DTF.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical trials in desmoid‐type fibromatosis in children and adults: A systematic review

Maren

Noesel

Husson

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…53 In 111 patients with DTs, ultrasound-guided HIFU provided a 36% 3-month tumor volume reduction rate with the most common adverse events (AEs) being pain (14%; all Grade 1 or 2) and bone reaction (10%; all Grade 1). 54 Percutaneous cryoablation uses argon gas through a sealed, segmentally insulated probe to cause rapid cooling. 53 This has been used in a limited number of patients with extraabdominal DTs and was associated with tumor volume reductions and symptom improvements with low rates of complications.…”

Section: Other Local Control Methodsmentioning

confidence: 99%

“…High‐intensity focused ultrasound (HIFU) is minimally invasive, using ultrasound beams precisely focused on target locations to produce thermal coagulation necrosis 53 . In 111 patients with DTs, ultrasound‐guided HIFU provided a 36% 3‐month tumor volume reduction rate with the most common adverse events (AEs) being pain (14%; all Grade 1 or 2) and bone reaction (10%; all Grade 1) 54 . Percutaneous cryoablation uses argon gas through a sealed, segmentally insulated probe to cause rapid cooling 53 .…”

Section: Local Control Strategiesmentioning

confidence: 99%

Evolving strategies for management of desmoid tumor

Riedel

Agulnik

2022

Cancer

View full text Add to dashboard Cite

Desmoid tumors (DTs) are rare soft tissue mesenchymal neoplasms that may be associated with impairments, disfigurement, morbidity, and (rarely) mortality. DT disease course can be unpredictable. Most DTs are sporadic, harboring somatic mutations in the gene that encodes for βcatenin, whereas DTs occurring in patients with familial adenomatous polyposis have germline mutations in the APC gene, which encodes for a protein regulator of βcatenin. Pathology review by an expert soft tissue pathologist is critical in making a diagnosis. Magnetic resonance imaging is preferred for most anatomic locations. Surgery, once the standard of care for initial treatment of DT, is associated with a significant risk of recurrence as well as avoidable morbidity because spontaneous regressions are known to occur without treatment. Consequently, active surveillance in conjunction with pain management is now recommended for most patients. Systemic medical treatment of DT has evolved beyond the use of hormone therapy, which is no longer routinely recommended. Current options for medical management include tyrosine kinase inhibitors as well as more conventional cytotoxic chemotherapy (e.g., anthracyclinebased or methotrexate-based regimens). A newer class of agents, γsecretase inhibitors, appears promising, including in patients who fail other therapies, but confirmation in Phase 3 trials is needed. In summary, DTs present challenges to physicians in diagnosis and prognosis, as well as in determining treatment initiation, type, duration, and sequence. Accordingly, evaluation by a multidisciplinary team with expertise in DT and patient-tailored management are essential. As management strategies continue to evolve, further studies will help clarify these issues and optimize outcomes for patients.

show abstract

“…In addition, DTs can occur in any part of the body, including the extra-abdominal, abdominal wall and intra-abdominal types. The safety and efficacy of HIFU ablation for different types of DTs also should be assessed [ 180 ].…”

Section: Magnetic Resonance Imaging Assessmentmentioning

confidence: 99%

Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams

Simonetti

Bruno

Fusco

et al. 2022

JPM

View full text Add to dashboard Cite

Desmoid tumors (DTs), also known as desmoid fibromatosis or aggressive fibromatosis, are rare, locally invasive, non-metastatic soft tissue tumors. Although histological results represent the gold standard diagnosis, imaging represents the fundamental tool for the diagnosis of these tumors. Although histological analysis represents the gold standard for diagnosis, imaging represents the fundamental tool for the diagnosis of these tumors. DTs represent a challenge for the radiologist, being able to mimic different pathological conditions. A proper diagnosis is required to establish an adequate therapeutic approach. Multimodality imaging, including ultrasound (US), computed tomography (CT) and Magnetic Resonance Imaging (MRI), should be preferred. Different imaging techniques can also guide minimally invasive treatments and monitor their effectiveness. The purpose of this review is to describe the state-of-the-art multidisciplinary imaging of DTs; and its role in patient management.

show abstract

The safety and ablation efficacy of ultrasound-guided high-intensity focused ultrasound ablation for desmoid tumors

Abstract: Chen (2021) The safety and ablation efficacy of ultrasound-guided highintensity focused ultrasound ablation for desmoid tumors,

Cited by 22 publications

References 36 publications

Clinical trials in desmoid‐type fibromatosis in children and adults: A systematic review

Clinical trials in desmoid‐type fibromatosis in children and adults: A systematic review

Evolving strategies for management of desmoid tumor

Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams

Contact Info

Product

Resources

About